Supplements for SIBO: An Honest Guide to a Contested Diagnosis

If you have spent months bloated, uncomfortable after almost everything you eat, and told that your tests are normal, SIBO can feel like the first explanation that actually fits. That experience is real, and the frustration behind it is legitimate. What follows is not a dismissal of it. But an honest guide has to separate two things that usually get merged: small intestinal bacterial overgrowth as a clinical condition, which is real and has been recognized for over a century, and the much broader idea that overgrowth explains ordinary bloating and IBS symptoms, which after twenty years of research remains unproven and is actively disputed inside gastroenterology. That distinction changes what you should do next.

What SIBO is, and what is contested

The classic condition is not in doubt. Excessive bacteria in the small intestine has been recognized for more than a century in people who have a structural or motility reason for it: previous bowel surgery, adhesions, strictures, scleroderma, or another condition that slows or obstructs flow through the small bowel. In those patients it produces diarrhea and genuine signs of malabsorption, and treating it is straightforwardly worthwhile.

What is contested is the extension of that idea. Roughly twenty years ago it was proposed that increased small-intestinal bacteria might also explain symptoms in people without malabsorption, in irritable bowel syndrome and related disorders. That proposal was productive: it pushed the field to take gut microbes seriously. But in 2024, a clinical practice update endorsed by both the European Society of Neurogastroenterology and Motility and the American Neurogastroenterology and Motility Society concluded that after two decades the hypothesis remains unproven, and that it has produced what the authors call serious unintended consequences: the widespread use of unreliable and unvalidated breath tests, and a resulting injudicious use of antibiotics. Their conclusion is blunt. They argue it is time to reject the hypothesis and its reliance on breath testing.

This is not a fringe position. The American Gastroenterological Association's own 2020 expert review opens by stating that the definition of SIBO as a clinical entity lacks precision and consistency, notes that controversy remains over its role in functional symptoms, and observes that a major impediment is our limited understanding of what a normal small-intestinal bacterial population even looks like. Meanwhile the American College of Gastroenterology published a full guideline in 2020 treating SIBO as a diagnosable, treatable entity. Both documents are serious, and they do not fully agree. When two major society documents and a third society-endorsed update pull in different directions, the correct consumer posture is caution, not certainty.

One terminology note that has practical consequences. Methane on a breath test does not come from bacteria at all. It comes from methanogenic archaea, a separate domain of life, and the overgrowth is not confined to the small bowel. The preferred term is now intestinal methanogen overgrowth (IMO) rather than methane SIBO. It matters because methane tends to track with constipation rather than diarrhea and is treated differently.

The breath test problem

Almost everyone who believes they have SIBO believes it because of a breath test. Here is what that test can and cannot tell you.

How it works. Human cells do not make hydrogen or methane, so any of either gas in your breath came from microbes fermenting carbohydrate. You fast, drink a sugar solution, and breathe into collection tubes at intervals. The 2017 North American Consensus, which is what most labs follow, set the operative thresholds: a rise in hydrogen of 20 parts per million or more above baseline by 90 minutes counts as positive, and a methane level of 10 parts per million or above counts as methane-positive. The familiar wording about methane counting at any point during the test, baseline included, comes from the 2020 ACG guideline rather than the consensus statement.

The accuracy is modest. A meta-analysis of 14 studies compared breath testing against small-bowel aspirate culture. Pooled sensitivity was 42 percent for the lactulose test and 54.5 percent for the glucose test. Specificity was 70.6 and 83.2 percent respectively. In plain terms, these tests miss half or more of culture-positive cases. And the pattern within that number matters enormously: for the glucose test, sensitivity was around 82 percent in people with a history of gastrointestinal surgery and around 41 percent in people with no predisposing condition at all. Two honest caveats: specificity actually moved the other way, 78.8 against 84.0 percent, so this is a statement about catching cases rather than avoiding false alarms, and the authors themselves only say the surgical group gave the impression of better performance. The direction is still the part that matters. The test picks up the most in exactly the patients who have a structural reason to suspect overgrowth, and the least in the people most likely to buy an at-home kit.

There is a design problem too. Lactulose is not absorbed, so it travels the whole small bowel and then reaches the colon, where fermentation is completely normal and expected. If food moves through your small intestine quickly, an early rise in hydrogen can simply be measuring fast transit rather than overgrowth. Researchers at Cedars-Sinai, who are among the strongest proponents of breath testing, say so themselves: the test is limited by its indirect method of measurement and by variability in how fast things move through the gut.

And the yardstick is bent. All of those sensitivity figures are measured against small-bowel aspirate culture as the reference standard. But the same ACG guideline that elsewhere calls aspirate culture the usual gold standard also concedes that endoscopic culture has not been established as a gold standard. Aspirates are prone to contamination on the way down, sample only the upper small bowel, and routinely miss fastidious anaerobes while not recovering the archaea that make up much of the relevant population. So we are validating an imperfect test against an imperfect standard, which is why the accuracy estimates vary so widely between studies.

None of this means a positive result is meaningless. It means a positive result is a piece of information to interpret with a clinician alongside your history, not a diagnosis to act on alone. It also means a negative result does not rule overgrowth out, which is worth knowing before you spend money re-testing.

What actually treats it

When overgrowth genuinely is present, the mainstream answer is antibiotics, and this is the part that most cleanly separates honest guidance from supplement marketing.

The 2020 ACG guideline makes exactly one treatment recommendation: it suggests antibiotics in symptomatic patients with SIBO, graded as a conditional recommendation based on a low level of evidence. It also cautions that an effort should be made to objectively diagnose SIBO before reaching for antibiotics, and warns about resistance, adverse reactions, and Clostridioides difficile.

The antibiotic usually used is rifaximin, which is poorly absorbed and therefore acts mostly in the gut. A meta-analysis of 32 studies in 1331 patients found an overall eradication rate of about 71 percent with a 4.6 percent rate of adverse events. But read the authors' own conclusion: the quality of the available studies is generally poor, and their opening paragraph notes that rifaximin gained popularity for this indication despite its use not being evidence-based. Nearly all of those studies measured breath-test normalization rather than whether people felt better, which inherits every problem described in the previous section. In the subset that did track symptoms, about 68 percent of the people whose overgrowth was eradicated improved. The deeper issue is the shape of the evidence base: in the ACG guideline's own breakdown of that same meta-analysis, only one of the 32 studies compared rifaximin against placebo.

Two practical points a supplement guide should be honest about. Rifaximin is not FDA-approved for SIBO; its US approvals are for IBS with diarrhea, hepatic encephalopathy, and travelers' diarrhea, so prescribing it here is off-label and insurers frequently decline it, which is why cash prices are a genuine barrier. And more importantly, both the ACG and AGA emphasize identifying and correcting the underlying cause where possible. A course of anything, herbal or pharmaceutical, does not fix an adhesion or a motility disorder, which is why recurrence is common.

The supplement shelf, honestly

There is a large and expensive market of SIBO protocols. Here is what each part of it actually rests on.

This table summarizes what published evidence exists, not whether any individual product is well made. Several of these are manufactured by reputable companies.

The herbal claim deserves a closer look, because it is the load-bearing one. In that 2014 study, patients who tested positive at a single referral center were treated with either rifaximin or a herbal combination, and 104 completed follow-up testing. Among them, 46 percent of the 37 herbal patients had a negative breath test compared with 34 percent of the 67 on rifaximin. That gets marketed as herbs outperforming antibiotics. In reality the study was not randomized, so patients chose their own treatment; the difference was not statistically significant at p equals 0.24; the endpoint was a breath test rather than symptoms; and both treatments failed in the majority of patients. It is a reasonable hypothesis that deserves a proper trial. It is not evidence of equivalence.

One signal worth watching, held to the same standard. A 2025 network meta-analysis of 30 randomized trials in 1552 people compared twelve SIBO treatments and ranked berberine highest for eradication in uncomplicated cases. That sentence gets quoted a lot, so it is worth looking at what sits underneath it. The berberine data come from a single open-label interim conference abstract in 46 patients, comparing berberine against rifaximin rather than against placebo. PubMed indexes that trial's protocol but no published results. Berberine's advantage over rifaximin did not reach statistical significance. And in that same uncomplicated-SIBO ranking, placebo scored above rifaximin, 60.4 against 48.8, which is a strong hint that the network is too thin to rank reliably. The authors say as much, describing their results as generating hypotheses for future validation in well-controlled, direct-comparison studies. Berberine also has meaningful drug interactions and additive blood-sugar effects. Treat this as the most interesting open question in the category, not as an answer.

The probiotic question

Probiotics occupy a strange position in this space: some protocols forbid them entirely, others sell them as the repair phase. The honest answer is that this is unsettled, and it is one of the few places where a supplement might plausibly make things worse.

The ACG guideline is direct: there is a lack of consistent data to support recommending specific probiotics in the treatment of SIBO. A 2018 study went further. Among patients with unexplained gas, bloating and brain fogginess, all of whom were taking probiotics, both bacterial overgrowth and D-lactic acidosis were more common than in those without brain fog, and symptoms improved in 77 percent after stopping the probiotics and taking a course of antibiotics.

That study should be read carefully rather than alarmingly. It was small, the intervention changed two things at once so you cannot separate stopping probiotics from taking antibiotics, and it drew several published rebuttals from other researchers. It is a signal, not a verdict. The practical takeaway: probiotics are not an established SIBO treatment, and if yours seem to be making bloating or mental fogginess worse, that is worth raising with a clinician, who may suggest stopping them. For where probiotics do have better evidence, see our guide to probiotic strains for IBS.

Diet, and where it goes wrong

Low-FODMAP is the best-evidenced dietary approach in this territory, but the evidence is for IBS symptom relief, not overgrowth eradication. Reducing fermentable carbohydrate reduces the substrate available to gut bacteria, which reduces gas and symptoms. That is symptom management, and a worthwhile thing. It is not antimicrobial. It also has an awkward implication for testing: if you have been restricting fermentable carbohydrate, a follow-up breath test may read negative simply because there was less substrate to ferment.

The bigger practical problem is that low-FODMAP was designed as a three-phase protocol: two to six weeks of restriction, then systematic reintroduction to find your actual triggers, then the least restrictive sustainable diet. In SIBO circles the restriction phase routinely becomes the permanent diet. That is a misuse of the protocol, and it carries real costs, including nutritional gaps, reduced microbial diversity, and for some people a slide toward disordered eating. Restriction is a diagnostic tool, not a destination. If you are going to do it, do it with a registered dietitian and with a plan to reintroduce.

Elemental diets, two weeks of an exclusively liquid formula of free amino acids and simple carbohydrate, have the most convincing mechanism of anything on the supplement side, since the nutrients are absorbed high in the small intestine. But the widely quoted 80 percent figure comes from a single uncontrolled open-label study from 2004 whose primary endpoint was breath-test normalization, with symptoms assessed only by a retrospective chart review a month later. They are also difficult, unpleasant, and expensive, and doing one unsupervised is not a good idea.

What to actually do

If you are bloated and miserable and looking for a plan, here is an honest one.

• Get evaluated properly first. Bloating and IBS-type symptoms have many causes with genuinely different treatments: IBS itself, celiac disease, carbohydrate malabsorption, gastroparesis, pelvic floor dysfunction, and others. Celiac disease in particular has a validated blood test and is worth excluding before anything else.
• Treat a breath test as one input, not a verdict. If you have already had one, take the result to a gastroenterologist rather than to a protocol. Bring your history, especially any prior abdominal surgery.
• If overgrowth is confirmed and treated, ask about the cause. Recurrence is common precisely because a course of treatment does not fix an underlying motility or structural problem.
• Use diet as a tool with an end date. Low-FODMAP with a dietitian, with a reintroduction plan, rather than indefinite restriction.
• Be skeptical of protocol stacking. If a plan includes a binder, a biofilm disruptor, a prokinetic, and a herbal antimicrobial, most of those components have no supporting evidence and some can interfere with medication absorption.

For symptom-level support while you get answers, the honest options are modest and well-scoped: peppermint oil has reasonable evidence for IBS-type cramping, and sensible fiber adjustments help some people. Those are symptom claims, not eradication claims, and they are a different thing from a SIBO cure. Our leaky gut guide takes a similar look at an adjacent and equally over-marketed idea, and the at-home gut test guide covers the wider consumer testing question. If a clinician does raise berberine with you, our berberine guide covers how the products differ.

Frequently asked questions

Is SIBO a real condition?

Yes, in its classic form. Bacterial overgrowth of the small intestine has been recognized for over a century in people with a clear predisposing cause, such as previous bowel surgery, adhesions, scleroderma, or another condition that slows or obstructs the flow through the small bowel. In those patients it produces diarrhea and signs of malabsorption, and treating it makes sense. What is contested is a newer and much broader idea: that bacterial overgrowth also explains bloating and IBS-type symptoms in people with no malabsorption and no predisposing condition. That hypothesis is more than twenty years old and, according to a 2024 clinical practice update endorsed by the European and American neurogastroenterology and motility societies, it remains unproven. So SIBO is real, but the version of SIBO that most people encounter online is a hypothesis rather than an established diagnosis.

How accurate is the SIBO breath test?

Less accurate than most people assume. A meta-analysis of 14 studies compared breath testing against small bowel aspirate culture and found pooled sensitivity of 42 percent for the lactulose test and 54.5 percent for the glucose test, meaning both miss half or more of culture-positive cases. Specificity was 70.6 and 83.2 percent. For the glucose test specifically, sensitivity was much better in people with a history of gastrointestinal surgery, around 82 percent, and much worse, around 41 percent, in people with no predisposing condition, which is precisely the group most likely to order an at-home kit. Specificity moved the other way, so that is a statement about catching cases rather than avoiding false alarms. There is also a design problem: lactulose is fermented by colonic bacteria too, so if food moves through your small intestine quickly, an early rise in hydrogen can reflect fast transit rather than overgrowth. And the comparison standard itself is imperfect, since the ACG guideline states that endoscopic culture has not been established as a gold standard.

What actually treats SIBO?

When overgrowth is genuinely present, the mainstream treatment is a course of antibiotics, and the antibiotic most often used is rifaximin. The 2020 American College of Gastroenterology guideline makes exactly one treatment recommendation, suggesting antibiotics for symptomatic patients with SIBO, and rates it a conditional recommendation based on a low level of evidence. A meta-analysis of 32 studies in 1331 patients found an overall eradication rate of about 71 percent, but the authors concluded the quality of the available studies is generally poor. Two practical points matter: rifaximin is not FDA-approved for SIBO, so it is prescribed off-label and often not covered by insurance, and identifying and correcting an underlying cause matters more for long-term outcomes than any single course of treatment. Either way, this is a prescription decision made with a doctor.

Do herbal antimicrobials work as well as antibiotics for SIBO?

That claim rests on far less than the marketing suggests. It traces almost entirely to a single 2014 study at one referral center in which patients who tested positive were treated with either rifaximin or a herbal combination, and 104 completed follow-up testing. Among them, 46 percent of the 37 people in the herbal group had a negative follow-up breath test compared with 34 percent of the 67 on rifaximin. Three things make that far weaker than it sounds. The study was not randomized, so patients chose their own treatment. The difference was not statistically significant, with a p-value of 0.24. And the outcome measured was a breath test rather than whether people felt better. Both groups also failed in the majority of cases. Randomized comparisons of a botanical against an antibiotic do exist, but there is still no placebo-controlled randomized trial of any herbal antimicrobial for SIBO, so the honest description is an interesting hypothesis that has not been properly tested, not an established equivalence to antibiotics.

Should I take probiotics if I think I have SIBO?

This is genuinely unsettled, and it is one of the few places where a supplement could plausibly make things worse. The ACG guideline states there is a lack of consistent data to support recommending specific probiotics in the treatment of SIBO. A 2018 study went further: among patients with unexplained gas, bloating and brain fogginess, all of whom were taking probiotics, both bacterial overgrowth and D-lactic acidosis were more common than in those without brain fog, and symptoms improved in 77 percent after stopping probiotics and taking a course of antibiotics. That study is small, the intervention combined two changes at once, and it drew several published rebuttals, so it is not the last word. The practical takeaway is simple: probiotics are not established as a SIBO treatment, and if yours are making bloating or mental fogginess worse, that is worth raising with a clinician, who may suggest stopping them.

What is methane SIBO, and is it different?

It is different enough that the name has changed. Methane on a breath test does not come from bacteria at all; it comes from methanogenic archaea, which are a separate domain of life, and the overgrowth is not confined to the small intestine. For both reasons the preferred term is now intestinal methanogen overgrowth, or IMO, rather than methane SIBO. Practically, methane tends to track with constipation rather than diarrhea, the threshold is a methane level of 10 parts per million or above, which the ACG guideline counts at any point during the test including baseline, and it is treated differently, often with a second antibiotic added. If you have been told you have methane SIBO, it is worth knowing the terminology has moved on, because it affects what treatment is appropriate.

The bottom line

SIBO is a real condition that has been stretched to cover a great deal it may not explain. If you have a structural or motility reason for overgrowth, testing and treatment make sense and belong with a gastroenterologist. If you are one of the far larger number of people with stubborn bloating, a positive at-home breath test, and a shopping cart full of herbal antimicrobials, the honest advice is to slow down: the test is unreliable in exactly your situation, the herbal evidence is one non-randomized study with a non-significant result, and several of the add-ons have no evidence at all. That is an unusual thing for a supplement site to conclude, which is precisely why it is worth saying. Get properly evaluated first. Your symptoms are real, and they deserve a real answer rather than an expensive protocol for a diagnosis nobody has confirmed.